Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CA4P with Paclitaxel and Carboplatin in Advanced Malignancies
NCT00113438Phase 2Completed
- Sponsor
- Oncotelic Therapeutics, Inc.
- Start
- Mar 2005
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fosbretabulin in solid tumor (advanced stage) (2 arms), sponsored by Oncotelic Therapeutics, Inc. Primary endpoints: Safety of CA4P-paclitaxel-carboplatin combination, Tumor Response and 2 more. Started Mar 2005; status: completed.
02
Drugs
fosbretabulin
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT00113438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113438.